Compare iShares Self-Driving EV and Tech (IDRV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs TransMedics Group Inc — how do they compare? iShares Self-Driving EV and Tech trades at $33.34 (market cap $264.50M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 10.4× iShares Self-Driving EV and Tech's market cap, and TransMedics Group Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and TransMedics Group Inc for 24 Days on average.
| IDRV | TMDX | |
|---|---|---|
Market Cap | $264.50M | $2.74B |
Volume | 48,021 | 949,331 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $150.42 |
52-Week Low | $32.68 | $61.99 |
Typical Hold Time | 73 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $33.34, down slightly (-0.06%) with a bearish technical signal. Moving averages indicate selling pressure while oscillators remain neutral. The stock faces resistance at $34 and support at $33. Recent news highlights mixed EV market conditions with strong European demand but weaker US adoption following subsidy changes. Chinese competition and regulatory uncertainties create headwinds for the sector.
The outlook remains cautious given technical weakness and sector challenges. Investment opportunity exists in global EV growth trends, particularly in Europe and China. Key risks include US regulatory uncertainty, Chinese market access restrictions, and volatile oil prices affecting consumer EV adoption decisions.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
